Allogeneic bone marrow transplantation as primary therapy for chronic myelomonocytic leukemia.

Abstract

This is the first report of a successful bone marrow transplantation for chronic myelomonocytic leukemia. A 41-year-old woman with chronic myelomonocytic leukemia received, as primary treatment, a novel preparatory regimen consisting of high dose fractionated total body irradiation and high dose VP-16 chemotherapy followed by allogeneic marrow transplantation from her histocompatible brother. The patient is now more than two years after marrow transplantation with normal blood counts and a normal bone marrow which is of donor type. For younger patients with this disease who have a histocompatible sibling donor, bone marrow transplantation may represent a valid therapeutic option with curative potential.

• Authors: S J Forman, M R O'Donnell, K G Blume, D I Feinstein
• Journal: Blut (Blut) Vol. 54 Issue 3 Pg. 189-92 (Mar 1987) ISSN: 0006-5242 [Print] Germany
• PMID: 3545328 (Publication Type: Case Reports, Journal Article, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Podophyllotoxin

Topics

• Adult
• Bone Marrow Transplantation
• Combined Modality Therapy (methods)
• Female
• Graft vs Host Disease (prevention & control)
• Humans
• Leukemia, Myeloid (blood, therapy)
• Podophyllotoxin (therapeutic use)
• Radiotherapy Dosage
• Remission Induction
• Time Factors
• Transplantation, Homologous